Homburger with Molecular Partners on $20m underwritten offering

On October 25, 2024, Homburger advised Molecular Partners, a clinical-stage biotechnology company, in the announcement of the pricing of an underwritten public offering. The offering consisted of 3,642,988 American Depositary Shares (ADSs), representing new shares, priced at $5.49 per ADS and aggregating to approximately $20 million in gross proceeds.

This offering was supported by a new investor, HBM Healthcare Investments, a prominent healthcare investment firm, alongside multiple existing investors.

Molecular Partners plans to allocate the net proceeds from the current offering toward expanding its
radiopharmaceutical pipeline, as well as for other general corporate activities.

Molecular Partner

Molecular Partners is a biopharmaceutical company headquartered in Zürich, Switzerland. The company focuses on DARPins, a class of small-protein therapies with potential applications in various disease
areas, including oncology, immuno-oncology, ophthalmology, and infectious diseases.

Homburger’s Team

Led by Dieter Gericke (right) and Karin Mattle (left) (both corporate/M&A, capital markets). It included Stefan Oesterhelt (tax), Lorenzo Togni, Romain Fakhoury and Hans Glent Abildgaard (all corporate/M&A, capital markets).

paolo.cannazza@lcpublishinggroup.com

SHARE